March 5th 2024
Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Radiotherapy Induced Taste Dysfunction During and 3 Months After Treatment in Head and Neck Cancer
August 1st 2022Treatment with radiotherapy for head and neck cancer resulted in taste dysfunction during treatment and 3 months thereafter, although reduction in oral cavity intensity-modulated radiotherapy dose may result in early taste function recovery.
Pembrolizumab, CRT Combo Misses EFS End Point in Unresected Locally Advanced HNSCC
July 22nd 2022The phase 3 KEYNOTE-412 trial assessing pembrolizumab and consolidation chemoradiotherapy plus maintenance pembrolizumab in unresected locally advanced head and neck squamous cell carcinoma missed its primary end point of event-free survival improvement vs matched placebo.
Toripalimab BLA Resubmission Accepted by FDA for the Treatment of Advanced Nasopharyngeal Carcinoma
July 8th 2022After receipt of a complete response letter in May 2022, a biologics license application for toripalimab monotherapy in the second line or later following platinum chemotherapy or in combination with chemotherapy in the first-line setting for advanced recurrent or metastatic nasopharyngeal carcinoma was resubmitted to and accepted by the FDA.
FDA Grants Fast Track Designation to PDS0101 Plus Pembrolizumab in Advanced Head and Neck Cancer
June 29th 2022Fast track designation was granted to PDS0101 plus pembrolizumab, which is currently being assessed in the phase 2 VERSATILE study in patients with recurrent or metastatic human papillomavirus 16–positive head and neck cancer.
Lifting the Stigma: The Importance of HPV Vaccination Education in Head and Neck Cancer
June 14th 2022Tom Thomas, MD, highlights how the stigma surrounding human papillomavirus–associated head and neck cancer is being unraveled through education and the importance of vaccination as a prevention strategy.
Tislelizumab Approved By China NMPA for Recurrent or Metastatic Nasopharyngeal Cancer
June 14th 2022Based on results of the phase 3 RATIONALE-309 trial, the China National Medical Products Administration has approved tislelizumab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal cancer.
Weekly Chemoradiotherapy and Cisplatin Non-Inferior to Cisplatin Every 3 Weeks in LA-SCCHN
June 1st 2022Chemoradiotherapy plus cisplatin administered weekly was found to be non-inferior to cisplatin once every 3 weeks for patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
FDA Issues Complete Response Letter to Toripalimab for Advanced Nasopharyngeal Carcinoma
May 3rd 2022Plans to resubmit a biologics license application for toripalimab as treatment of advanced recurrent or metastatic nasopharyngeal carcinoma have been made for midsummer 2022 following receipt of a complete response letter from the FDA.
First-Line Tislelizumab Plus Chemotherapy Could Become SOC in Nasopharyngeal Cancer
April 20th 2022Investigators of the phase 3 RATIONALE-309 trial found an improvement in progression-free survival for patients with recurrent or metastatic nasopharyngeal cancer treated with tislelizumab plus chemotherapy vs chemotherapy alone.
Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN
March 2nd 2022Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.
Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal Cancers
February 25th 2022Research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium highlighted the potential to detect oropharyngeal cancer recurrence using circulating tumor tissue modified viral–human papillomavirus DNA.
Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell Carcinoma
February 25th 2022A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.
DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCC
February 25th 2022In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.